Bend Bioscience

From formulation to finish, Bend delivers bold science and seamless support to move your molecule forward.

Looking for a better path for your rare disease molecule? When every patient counts, precision and flexibility matter. Rare disease development demands more than expertise. It requires a CDMO built for small scale, tight timelines, and complex formulations — without compromising quality or compliance.

We’re excited to join the Advancing Drug Development Forum next week, where Dr. Michael Grass, Bend Bioscience’s Head of Innovation, will speak on the Beyond Rule of 5 (bRo5) Roundtable: “Enabling bRo5 Advanced Technologies for Development.” This session brings together experts discussing the formulation and delivery technologies that help advance non-traditional small molecules — including round tablets, lipid systems, nanoparticles, RNA-targeted small molecules, and emerging AI-enabled approaches. Roundtable Details: 📅 December 11, 2025 🕒 3:00 PM — Enabling bRo5 Advanced Technologies for Development 🎙 Speakers: Michael Grass (Bend Bioscience), Erica Schlesinger (Serán BioScience), Frank Tagliaferri (Pace Life Sciences), 💼 Session Chair: Hector Guzman, Newleos Therapeutics Our Business Development team — Marinn Hersh and Jared A. Hersh will also be on-site throughout the summit. If you’re attending, connect with them to learn more about how Bend’s High Science + High Service approach accelerates complex small-molecule development. See you in Boston! #bRo5 #BeyondRuleOf5 #DrugDevelopment #FormulationScience #BendBioscience #AdvancedDrugDelivery #PharmaInnovation #CDMO #HighScienceHighService

📊 What’s shaping the future of pharma development? Join Gwen Green, Chief Commercial Officer at Bend Bioscience, for a virtual panel hosted by Orientation Marketing and CPHI Informa. Alongside fellow CDMO and pharma leaders, Gwen will explore what’s ahead for drug development and manufacturing — from scale-up strategies and regulatory shifts to technology-driven partnerships that are redefining the CDMO model. At Bend Bioscience, we’re proud to deliver High Science + High Service at every stage. Gwen’s insights will showcase how our U.S.-based CDMO is expanding capabilities — including commercial spray drying — and setting a new standard for agility, technical excellence, and true partnership in the pharma services space. 👉 Register here: https://lnkd.in/ekNJAXqx 📩 Want to dive deeper? DM us to connect at CPHI in Frankfurt.

🌍 Heading to Frankfurt for CPHI Worldwide? Let’s connect! Bend Bioscience is excited to be attending CPHI Worldwide October 28-30 in Frankfurt, Germany — and we’re bringing a powerhouse team including Rachel L. Timberlake, MBA, Gwen Green, Michael Floegel, Michael Boyle, and Amber Broadbent, all ready to talk oral dose development and manufacturing. ✅ Clinical to Commercial Oral Manufacturing ✅ End-to-End Spray Dry Solution ✅ Controlled Release & Multiparticulates ✅ Accelerated, Rare & Orphan Programs Whether you're navigating a tough formulation challenge or exploring a new CDMO partnership, we’d love to meet. 📍 Stop by Booth #5.1A49 📬 Or DM us to schedule time with the team — we’re ready to help make your molecule remarkable. 🔗 www.bendbioscience.com #CPHIWorldwide #BendBioscience #HighScienceHighService #BolderScienceBiggerImpact #CDMO

🚨 Big News from Bend Bioscience 🚨 We’re excited to unveil our bold new look — one that reflects who we are, what we stand for, and where we’re headed. At Bend Bioscience, we’re a US-based small-molecule pharmaceutical CDMO with a mission to amplify the potential of medicines. Our refreshed brand captures the essence of what drives us: 🧪 High Science. 🤝 High Service. 💥 Bolder Science. Bigger Impact. We’re still the same expert CDMO partner you trust — now with a look as precise and forward-thinking as the work we do. 🔗 Follow along and discover how we’re bending science toward something remarkable. https://lnkd.in/gCEwvE8H #BendBioscience #CDMO #PharmaceuticalDevelopment #SmallMolecule #HighScienceHighService #BolderScienceBiggerImpact #BrandReveal